Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rare Diseases 1Lung Neoplasms 1Graft vs Host Disease 1Gastrointestinal Diseases 1Fatigue 1Crohn Disease 1Colitis, Ulcerative 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Bronchiolitis Obliterans Syndrome 1Anorexia 1

Interventions

Fluorouracil 3Bevacizumab 3Oxaliplatin 2Leucovorin 2Irinotecan 2trifluridine tipiracil drug combination 1sintilimab 1napabucasin 1encorafenib 1S-1 plus cisplatin 1Paclitaxel 1Oviposition 1Levoleucovorin 1Infliximab 1Drug Therapy 1Drainage 1Cisplatin 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Gastrointestinal Diseases × Infliximab × Clear all
NCT00004941 2015-03-25

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
94 enrolled
Gastrointestinal

Crohn Disease, Gastrointestinal Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡